Antibe Therapeutics Inc(Pre-Merger)

TSX:ATECanadaView on OTC Pink - Current Information

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

Contact Information

Headquarters

15 Prince Arthur AvenueTORONTO, ON, Canada M5R 1B2

Phone

905-726-0995

Fax

905-570-5103

Executives

Independent Chairman of the Board

Robert Hoffman

President, Chief Executive Officer, Secretary, Director

Daniel Legault

Vice Chairman of the Board

Walter Macnee

Chief Financial Officer

Alain Wilson

Chief Operating Officer

Scott Curtis